Rapid learning in practice: A lung cancer survival decision support system in routine patient care data

Abstract

Background and purpose A rapid learning approach has been proposed to extract and apply knowledge from routine care data rather than solely relying on clinical trial evidence. To validate this in practice we deployed a previously developed decision support system (DSS) in a typical, busy clinic for non-small cell lung cancer (NSCLC) patients. Material and methods Gender, age, performance status, lung function, lymph node status, tumor volume and survival were extracted without review from clinical data sources for lung cancer patients. With these data the DSS was tested to predict overall survival. Results 3919 lung cancer patients were identified with 159 eligible for inclusion, due to ineligible histology or stage, non-radical dose, missing tumor volume or survival. The DSS successfully identified a good prognosis group and a medium/poor prognosis group (2 year OS 69% vs. 27/30%, p < 0.001). Stage was less discriminatory (2 year OS 47% for stage I–II vs. 36% for stage IIIA–IIIB, p = 0.12) with most good prognosis patients having higher stage disease. The DSS predicted a large absolute overall survival benefit (~40%) for a radical dose compared to a non-radical dose in patients with a good prognosis, while no survival benefit of radical radiotherapy was predicted for patients with a poor prognosis. Conclusions A rapid learning environment is possible with the quality of clinical data sufficient to validate a DSS. It uses patient and tumor features to identify prognostic groups in whom therapy can be individualized based on predicted outcomes. Especially the survival benefit of a radical versus non-radical dose predicted by the DSS for various prognostic groups has clinical relevance, but needs to be prospectively validated.

A validated tumor control probability model based on a meta‐analysis of low, intermediate, and high‐risk prostate cancer patients treated by photon, proton, or carbon‐ion radiotherapy

“…Evolution in clinical practice produces legacy issues for modeling. 80,81 In this study, bNED is defined by either the American Society for Therapeutic Radiology and Oncology (ASTRO-three consecutive PSA rises post the PSA nadir) or the Phoenix Consensus Conference (PCC-2 ng/ml PSA rise above the PSA nadir) definition of biochemical failure. 82 Control rates defined by the ASTRO definition appear to be worse at 2-5 yr, are convergent at 5-8 yr, and superior at 8-12 yr in comparison with the PCC definition.…”

Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data

“…Prototype efforts such as our MRLU could inform further development of efforts such as CancerLinQ. Similar, disease-specific RLS tools like the MRLU have also been reported for other diseases, including for lung cancer [42]. …”

Regional Process Redesign of Lung Cancer Care: A Learning Health System Pilot Project

“…There has been a call to realize the lhs vision through practical implementations 26 , and oncology has made an effort to answer this call. However, gaps remain 27,28 .…”